A5061626918- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Renal and related cancers
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Urological Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Testicular diseases and treatments
- Multiple and Secondary Primary Cancers
- Childhood Cancer Survivors' Quality of Life
- Esophageal Cancer Research and Treatment
- Multiple Myeloma Research and Treatments
- Hormonal and reproductive studies
- Ferroptosis and cancer prognosis
- Colorectal Cancer Screening and Detection
- Bone health and treatments
- Inflammatory Biomarkers in Disease Prognosis
University of Alberta
2016-2025
Cancer Institute (WIA)
2011-2023
BC Cancer Agency
2007-2022
Alberta Cancer Foundation
2010-2022
University of Calgary
2022
AstraZeneca (Poland)
2021
Astellas Pharma (China)
2021
Bayer (United States)
2021
Clinical Trials New Zealand
2021
Astellas Pharma (United Kingdom)
2021
Biosynthesis of extragonadal androgen may contribute to the progression castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor biosynthesis, prolongs overall survival among patients with metastatic cancer who have received chemotherapy.We randomly assigned, in a 2:1 ratio, 1195 had previously docetaxel receive 5 mg prednisone twice daily either 1000 acetate (797 patients) or placebo (398 patients). The primary end point was survival. secondary points...
There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated vascular endothelial growth factor (VEGF) -targeted therapy.Baseline characteristics and outcomes 645 anti-VEGF therapy-naïve RCC were collected from three US four Canadian cancer centers. Cox proportional hazards regression, followed by bootstrap validation, was used to identify independent OS.The median OS the whole cohort 22 months (95% CI, 20.2 26.5...
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, or without early docetaxel, will improve metastatic, hormone-sensitive cancer.In this open-label, randomized, phase 3 trial, we assigned patients receive suppression plus either open-label a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point...
Vascular endothelial growth factor targeted therapy is a standard of care in patients with metastatic renal cell carcinoma. The role cytoreductive nephrectomy the era novel agents remains poorly defined.We retrospectively reviewed baseline characteristics and outcomes 314 anti-vascular naïve, carcinoma from United States Canadian cancer centers to study impact on overall survival.Patients who underwent (201) were younger (p < 0.01), more likely have better Karnofsky performance status than 1...
This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal carcinoma (nccRCC). In addition, survival outcome of nccRCC patients was characterized.Data on 2215 (1963 with clear-cell RCC [ccRCC] and 252 nccRCC) treated first-line VEGF- mTOR-targeted therapies were collected from IMDC. Time treatment failure (TTF) overall (OS) compared groups favorable, intermediate, poor prognoses according IMDC criteriaThe median OS entire...
18 Background: Pts who have progressed on a prior NHT and mCRPC with extrapelvic nodal or visceral metastasis poor prognosis limited, broadly available treatment options beyond chemotherapy. C promotes an immune-permissive tumor environment may enhance response to immune checkpoint inhibitors (ICIs). Methods: randomized 1:1 C+A (C [40 mg PO QD] + A [1200 IV Q3W]) control (ctrl) (abiraterone [1000 prednisone [5 BID] enzalutamide [160 QD]) were stratified by liver (yes/no), docetaxel for mCSPC...
The objective of this study was to evaluate the efficacy and safety atrasentan (Xinlay), a selective endothelin-A receptor antagonist, in patients with metastatic hormone-refractory prostate cancer (HRPC).This multinational, double-blind, placebo-controlled trial enrolled 809 men HRPC. Patients were randomized 1:1 receive either 10 mg per day or placebo. primary endpoint time disease progression (TTP), which determined according radiographic clinical measures. Analyses overall survival...
To determine the clinical activity of OGX-011, an antisense inhibitor clusterin, in combination with docetaxel/prednisone patients metastatic castration-resistant prostate cancer.Patients were randomly assigned 1:1 to receive either (arm A) or without B) OGX-011 640 mg intravenously weekly. The primary end point was proportion a prostate-specific antigen (PSA) decline ≥ 50% from baseline, experimental therapy being considered interest if PSA more than 60%. Secondary points objective response...
Purpose: Targeted agents and immunotherapies promise to transform the treatment of metastatic bladder cancer, but therapy selection will depend on practical tumor molecular stratification. Circulating DNA (ctDNA) is established in several solid malignancies as a minimally invasive tool profile genome real-time, critically underexplored cancer.Experimental Design: We applied combination whole-exome sequencing targeted across 50 cancer driver genes plasma cell-free (cfDNA) from 51 patients...
T esticular tumours are uncommon but constitute an important group of malignancies in young men.Worldwide, it is estimated that there were more than 48 500 new cases and 8900 deaths from the disease 2002. 1 The vast majority primary germ cell (GCTs) incidence has doubled past 30 years (with most increase seminomas). 2 While patients present with early-stage highly curable disease, continued rise these presents a major challenge.Germ testicular common solid males between ages 20 35; 2008 will...
Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This study tested custirsen, a CLU inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or within 6 months of initial docetaxel therapy.Men were randomized to receive either + prednisone custirsen (DPC) mitoxantrone (MPC).Forty-two received treatment. Toxicity was similar both arms. Twenty treated DPC median 8 cycles; overall...
Testicular cancer survivors (TCS) are at increased risk of cancer-related fatigue (CRF), psychosocial impairment, and poor mental health-related quality life (HRQoL). Here, we examine the effects high-intensity interval training (HIIT) on patient-reported outcomes (PROs) in TCS. Secondarily, explore cardiorespiratory fitness as a mediator intervention select baseline characteristics moderators effects.TCS (n = 63) were randomly assigned to 12 weeks supervised HIIT or usual care (UC). PROs...
Agents that have shown improvements in survival mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents palliative radiation continue to play an important role the overall management of mCRPC. Given complexity, variety importance optimizing use these agents, a multidisciplinary team approach is highly recommended.